Loading
A phase 1/2 trial of BNT324 and PM8002 in advanced solid tumours, run by BioNTech SE, now recruiting.
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer is a phase 1/2 interventional study registered as NCT06892548 by BioNTech SE, with 594 participants planned, started 2025-05-02 and due to reach its primary completion in 2028-09. Interventions recorded: BNT324 and BNT327.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares BNT324, Duality Biotherapeutics, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares BNT324, Duality Biotherapeutics, PM8002, BioNTech and the tag pipeline.
Shares Duality Biotherapeutics, PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/